Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2008

View Archived Issues

Recent Bayer Schering Pharma patents disclose novel contraceptive agents

Chelsea granted U.K. approval for phase II droxidopa trial in fibromyalgia

Dendreon expects interim data analysis for IMPACT trial in October 2008

GP Pharm completes phase III Lutrate trial in advanced prostate cancer

HT-0712 primate study reveals significant enhancement of long-term memory

Janumet approved in the E.U. for type 2 diabetes

MethylGene and Celgene temporarily suspend new enrollment in MGCD-0103 trial

ProQuin XR achieves first E.U. marketing authorization in Sweden

Medicure able to fund operations until the end of 2008

Teva's acquisition of Bentley Pharmaceuticals completed

Health Canada grants approval to Santhera's Catena in Friedreich's ataxia

Novel radiotracer useful for imaging CB1 type receptors in schizophrenia

Combined statin and biphosphonate treatment shows promise in mouse model of human progeria

[11C]-CUMI-101, a novel radioligand with potential use in imaging 5-HT1A receptors

Vitespen fails to improve recurrence-free survival in high-risk renal cell carcinoma patients

FDA issues nonapprovable letter in response to NexMed's NDA for a topical treatment for ED

New agents for treating psychiatric disorders reported in recent AstraZeneca and Abbott patents

New oncolytic agents imparted in recent patents

Ipsen presents an update on the company's acquisition of Tercica

Roche to acquire Arius Research

Santarus and Depomed enter U.S. promotion agreement for Glumetza for type 2 diabetes

Emergent BioSolutions and University of Oxford form joint venture to develop MVA-85A

FDA grants regulatory clearance to Response Biomedical to market Ramp NT-proBNP test for HF

OncoVista Innovative initiates enrollment in phase I/II study of cordycepin

Talecris' aerosolized alpha1-antitrypsin designated orphan drug in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...